Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Next Previous
X
Search
Trial Profile

A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 31 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
  • Indications Malignant-mesothelioma
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE 483

    • Most Recent Events

    • 29 May 2024 According to a Merck Sharp & Dohme media release, based on data from this trial the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, in combination with chemotherapy, for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of September 25, 2024.
    • 12 Jan 2024 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.
    • 07 Nov 2023 Results assessing whether the addition of pembrolizumab to platinum pemetrexed would improve overall survival in patients with pleural mesothelioma, published in the Lancet
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top